• 1
    Aus G, Hugosson J, Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995; 154: 4606
  • 2
    Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 62631
  • 3
    Grönberg H, Damber J-E, Jonsson H, Lenner P. Patient age as a prognostic factor in prostate cancer. J Urol 1994; 152: 8925
  • 4
    Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 426
  • 5
    Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994; 331: 9961004
  • 6
    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 2226
  • 7
    Christensson A, Björk T, Nilsson O et al. Serum-prostate specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 1005
  • 8
    Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992; 4 (suppl.): 12938
  • 9
    Stamey TA. Making the most out of six systemic sextant biopsies. Urology 1995; 45: 212
  • 10
    Mitrunen K, Pettersson K, Piironen T et al. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995; 41: 111520
  • 11
    Pettersson K, Piironen T, Seppälä M et al. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map and development of immuno-fluorometric assays for specific and sensitive detection of free PSA and PSA-alpha-1-antichymotrypsin complex. Clin Chem 1995; 41: 14808
  • 12
    Kane RA, Littrup PJ, Babaian R et al. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer society National prostate cancer detection project. Cancer 1992; 69: 12017
  • 13
    Labrie F, Candas B, Cusan L et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996; 47: 2127
  • 14
    Catalona WJ, Smith DS, Ratliff TL et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 94854
  • 15
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer I. Results of a retrospective evaluation of 1726 men. Urology 1995; 46: 7738
  • 16
    Gustafsson O, Norming U, Almgård LE et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol 1992; 148: 182731
  • 17
    Prostatacancer Primärregistrering 1996. Regionalt Onkologiskt Centrum i Uppsala/Örebroregionen. ISBN 91–87934–77–9, 1998
  • 18
    Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localised prostate cancer. J Urol 1993; 150: 1104
  • 19
    Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localised prostate cancer. Urology 1996; 48: 24954
  • 20
    Lodding P, Aus G, Bergdahl S et al. Characteristics of screening detected prostate cancer in men 50–66 years old with 3–4 ng/mL. Prostate specific antigen. J Urol 1998; 159: 899903
  • 21
    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6–4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 14525
  • 22
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part II. Retrospective analysis of free to total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 1995; 46: 77984
  • 23
    Luderer AA, Chen Y-T, Soriano TF et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic grey zone of total prostate-specific antigen. Urology 1995; 46: 18794